ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 1359

Association of Menstrual Cycles and Disease Flare Activity in Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Abstract Number: 1360

Factors Associated with Medication-related Concerns in Women with Inflammatory Rheumatic Diseases – an Analysis of a Nationwide Pregnancy Cohort
Abstract Number: 1361

Effect of Zen/Doria Remission and Glucocorticoid Dosage on the Pregnancy Outcome of SLE: Retrospective Study in Two Japanese Tertiary Referral Centers
Abstract Number: 1362

Improving Reproductive Health Counseling for Pediatric Adolescent Females Prescribed Teratogenic DMARDs
Abstract Number: 1363

Plasma Neutrophil Extracellular Trap Remnant Levels Are Lower in Premenopausal Healthy Women Using Oral Contraceptive Pills
Abstract Number: 1364

Both Low and High 25(OH)-Vitamin D Levels Increase Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus
Abstract Number: 1365

Extraglandular Involvement and Autoantibody Status as Risk Factors for Cardiovascular Disease in Primary Sjogren’s Syndrome (pSS): A 20 Year-follow up Study
Abstract Number: 1366

A Unique Cluster of Inflammatory Monocytes and Functionally Intact Regulatory T Cells in Rare Childhood Sjögren’s Disease
Abstract Number: 1367

Novel Autoantibodies Might Circumvent the Need for Labial Biopsy in a Subset of Seronegative Sjögren’s Disease Patients
Abstract Number: 1368

Development of the Sjögren’s-related Quality of Life (SRQoL) to Assess Health-related Quality of Life (HRQoL) in Sjögren’s
Abstract Number: 1369

Treatment Patterns and Drivers of Biologic Prescriptions in Patients with Primary Sjögren’s Disease: Results from a Multinational, Real-World Survey
Abstract Number: 1370

Synthetic Glabridin Derivatives Improves Sjogren’s Syndrome by Inducing Salivary Secretion and Salivary Gland Regeneration
Abstract Number: 1371

Are Ultrasound Salivary Parenchymal Abnormalities More Severe in Primary Sjögren Patients with a Higher Disease Duration ? A Cross-sectional International Study
Abstract Number: 1372

Obinutuzumab Efficacy and Tolerance in Patients with Auto-Immune Diseases Immunized Against Rituximab
Abstract Number: 1373

Deltex1 May Involve the Function of T Regulatory Cells and Regulate the Disease Activity of Sjögren’s Syndrome

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].